Literature DB >> 8679270

Targeted radiotherapy of osteosarcoma using 153 Sm-EDTMP. A new promising approach.

O S Bruland1, A Skretting, O P Solheim, M Aas.   

Abstract

We report a case where targeted radionuclide therapy using 153Sm-EDTMP gave substantial palliative effect. A 35-year-old male with a primary osteosarcoma located in the first lumbar vertebra relapsed with progressive back pain after conventional treatment modalities had failed. He became bedridden, and developed paraparesis and impaired bladder function. On a diagnostic bone-scan intense radioactivity was localized in the tumor. He therefore was given 153Sm-EDTMP treatment twice, 8 weeks apart, 35 and 32 MBq/kg body weight respectively. After a few days the pain was significantly relieved and by the second radionuclide treatment the pareses subsided. For six months he was able to be up and about without any neurological signs or detectable metastases. Eventually, however, he experienced increasing local pain, developed paraparesis, was re-operated but died 4 months later. The dramatic transient improvement observed in this case warrants further exploration using 153Sm-EDTMP as a boost technique, supplementary to conventional external radiotherapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8679270     DOI: 10.3109/02841869609101655

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  9 in total

Review 1.  The multidisciplinary management of osteosarcoma.

Authors:  Noah Federman; Nicholas Bernthal; Fritz C Eilber; William D Tap
Journal:  Curr Treat Options Oncol       Date:  2009-02-24

2.  [Osteosarcoma of the pelvisTwo case reports and review of the literature].

Authors:  S Bading; E Mössinger; H Rosenthal; F Länger; L Bastian
Journal:  Unfallchirurg       Date:  2004-07       Impact factor: 1.000

3.  Intratumour injection of immunoglobulins labelled with the alpha-particle emitter 211At: analyses of tumour retention, microdistribution and growth delay.

Authors:  R H Larsen; O S Bruland
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

4.  Beyond Palliation: Therapeutic Applications of 153Samarium-EDTMP.

Authors:  Breelyn A Wilky; David M Loeb
Journal:  Clin Exp Pharmacol       Date:  2013-06

5.  Two cases with fatal outcome following total lung irradiation for metastatic bone sarcoma.

Authors:  K Lia; Ø S Bruland; H L Randem; L H Aksnes; J P Poulsen; I Taksdal; K Sundby Hall
Journal:  J Bone Oncol       Date:  2013-10-11       Impact factor: 4.072

6.  Novel Human Antibodies to Insulin Growth Factor 2 Receptor (IGF2R) for Radioimmunoimaging and Therapy of Canine and Human Osteosarcoma.

Authors:  Jaline Broqueza; Chandra B Prabaharan; Samitha Andrahennadi; Kevin J H Allen; Ryan Dickinson; Valerie MacDonald-Dickinson; Ekaterina Dadachova; Maruti Uppalapati
Journal:  Cancers (Basel)       Date:  2021-05-04       Impact factor: 6.639

7.  Current therapeutic strategies and novel approaches in osteosarcoma.

Authors:  Kosei Ando; Marie-Françoise Heymann; Verena Stresing; Kanji Mori; Françoise Rédini; Dominique Heymann
Journal:  Cancers (Basel)       Date:  2013-05-24       Impact factor: 6.639

8.  Clinical Epidemiology of Low-Grade and Dedifferentiated Osteosarcoma in Norway during 1975 and 2009.

Authors:  Kjetil Berner; Tom Børge Johannesen; Øyvind S Bruland
Journal:  Sarcoma       Date:  2015-08-30

9.  Radioimmunotherapy Targeting IGF2R on Canine-Patient-Derived Osteosarcoma Tumors in Mice and Radiation Dosimetry in Canine and Pediatric Models.

Authors:  Jaline Broqueza; Chandra B Prabaharan; Kevin J H Allen; Rubin Jiao; Darrell R Fisher; Ryan Dickinson; Valerie MacDonald-Dickinson; Maruti Uppalapati; Ekaterina Dadachova
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.